#### 1 TITLE PAGE

#### 2

**Five-Year Survival Outcomes for Breast Cancer** 3 **Patients Across Continental Africa: A Contemporary** 4 **Review of Literature with Meta Analysis** 5 6 Augustina Badu-Peprah<sup>1,2,†</sup>, Ernest Kissi Kontor<sup>3,†,\*</sup>, Adu-Gyamfi Benjamin<sup>2</sup>, Jessica Kumah<sup>4</sup>, 7 Akosua Aya Essuman<sup>5</sup>, Bossoh Selorm<sup>3</sup>, Issahak Nurudeen<sup>3</sup>, Bismark Osei Owusu<sup>6</sup>. and 8 Nitvanand Jain 7,\* 9 <sup>1</sup>Department of Radiology, Kwame Nkrumah University of Science and Technology, Kumasi, AOK385 Ghana 10 <sup>2</sup> Department of Radiology, Komfo Anokye Teaching Hospital, Kumasi, AOK385 Ghana 11 12 <sup>3</sup> Department of Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, Kumasi, AOK385 Ghana 13 14 <sup>4</sup> Department of Environmental Health Sciences, University of Massachusetts Amherst, MA 01003 United States 15 <sup>5</sup> Department of Biology, Georgia State University, Atlanta, GA 30302 United States 16 <sup>6</sup> Internal Medicine Directorates, Komfo Anokye Teaching Hospital, Okomfo Anokye Road, Kumasi AK034, Ghana 17 <sup>7</sup> Independent Statistical Consultant, Chandigarh, Chandigarh Capital Region, 160036 India 18 19 \*Corresponding Authors

- 20 *†* Co-first authors (contributed equally)
- 21

23

25

27

29

31

33

35

37

- 22 Additional Author Information
- 24 Augustina Badu-Peprah, Email: <u>augustinabadupeprah@gmail.com</u>; ORCID: 0000-0003-0979-4006
- 26 Ernest Kissi Kontor, Email: <u>ernestkissikontor@gmail.com</u>; ORCID: 0000-0001-7349-8012
- 28 Adu-Gyamfi Benjamin, Email: adugyamfibenjamin210@gmail.com; ORCID: 0009-0000-0417-8074
- 30 Jessica Kumah, Email: jkumah@umass.edu; ORCID: 0009-0003-7346-3188
- 32 Akosua Aya Essuman, Email: <u>akosuaaya29@gmail.com</u>; ORCID: 0009-0008-9709-6905
- 34 Bossoh Selorm, Email: <a href="mailto:selormbossoh@gmail.com">selormbossoh@gmail.com</a>; ORCID: 0009-0003-6872-6051
- 36 Issahak Nurudeen, Email: <u>nurudeenissahak09@gmail.com</u>; ORCID: 0009-0008-1280-2031
- 38 Bismark Osei Owusu, Email: <u>bhismarkoseiowusu@gmail.com</u>; ORCID: 0009-0008-2589-799X
- 40 Nityanand Jain, Email: <u>nityapkl@gmail.com</u>; ORCID: 0000-0002-7918-7909
- 41 42
- 43
- 44

#### 45 Abstract

#### 46 Background

Breast cancer associated mortality in Africa remains high due to poor survival rates, varying
widely across countries. Despite medical advancements, barriers like limited access to early
detection and treatment persist. This meta-analysis offers a crucial update on 5-year survival
trends and influencing factors across continental Africa.

51

## 52 Methods

A systematic search of four biomedical databases and citation searching identified 79 articles from 22 African countries, analyzing 27,559 patients (97% female). A random-effects model was used to estimate the 5-year survival rate with subgroup analyses. Publication bias was assessed

- 56 using Egger's test and funnel plots.
- 57

# 58 **Results**

Pooled overall 5-year breast cancer survival in Africa averaged 48% (95% CI: 43-53%) with 59 high statistical heterogeneity ( $I^2 = 98\%$ ). Survival was highest in Northern Africa (64%; 95% CI: 60 61 59-69%) and lowest in Western Africa (32%; 95% CI: 23-42%). Males (51%; 95% CI: 36-65%) had marginally higher survival than females (48%; 95% CI: 42-54%). Socioeconomic indices 62 were positively associated with better outcomes. Publication bias, adjusted by the trim-and-fill 63 64 method, raised survival to 62% (95% CI: 55-67%). A country-wise comparison with 2018 estimates suggests a declining survival tendency, with WHO AFRO countries reporting the 65 poorest estimates among other WHO regions. Despite regional differences, survival trends seem 66 to have plateaued near 48-49% level continent-wide since the early 2010s. 67

68

# 69 Conclusions

Our findings reveal marked regional disparities in survival rates across Africa, underscoring the
 urgent need for targeted healthcare interventions. Strengthening healthcare systems, ensuring
 universal access, and driving socioeconomic progress are vital to improving survival outcomes.

73

75

74 Keywords: breast cancer; Africa; survival; surveillance; cumulative meta-analysis.

## 76 **1. Introduction**

77 Breast cancer remains a significant global health concern that affects both women and men, despite the considerable progress made in early diagnostics and treatment modalities [1]. It 78 is the most prevalent malignant disease among women worldwide and is the second leading 79 80 cause of cancer-related mortality [2,3]. The heterogeneity and complexity in managing breast cancer is underscored by its multiple subtypes, which exhibit varying biological behaviors and 81 clinical responses to treatment [4,5]. Notwithstanding substantial advancements in early 82 83 detection and therapeutic strategies, significant survival disparities persist between high-income and low- to middle-income countries [6,7]. 84

In Africa, the burden of breast cancer is particularly pronounced, with incidence and mortality rates continuing to rise. The latest estimates indicate that breast cancer leads to an estimated 186,598 new cases and 85,787 deaths annually among Africans [8]. Notably, regional variations in disease burden have been observed within the continent, with the highest incidence of new cases occurring in Northern and Western Africa [9]. Contributing factors include delayed

diagnosis, inadequate healthcare infrastructure and funding, insufficient public health education
 initiatives, mistrust in western medicine, and significant socioeconomic barriers.

The most recent 5-year survival estimates for African countries were reported by a metaanalysis conducted by Ssentongo et al. [10]. Their study, which was limited to a search strategy till October 2018, determined that the overall 5-year survival rate in Africa was 52.9%. Subsequently, no further estimates have been collated, potentially resulting in a discrepancy between the literature and the situation on the ground. Cochrane suggests that updates should occur biennially, while Campbell reviews recommend that updates occur within a five-year cycle to facilitate the accumulation of knowledge [11].

99 These updates are driven by the rapid evolution of medical research and treatment 100 methodologies, which may not align with current practices, advancements, or emerging trends 101 observed six years ago. Additionally, the socioeconomic and healthcare landscapes in Africa are 102 subject to continual change influenced by several factors, including policies, investments, and 103 regional partnerships. These dynamics can significantly impact breast cancer diagnosis, 104 treatment, and survival outcomes, highlighting the necessity for an updated analysis.

Hence, we believe that the integration of more recent data allows for a detailed and updated analysis of survival outcomes in Africa. The findings from our study will provide insights that can be acted upon, offering a detailed understanding of the factors influencing breast cancer survival across diverse African contexts. Such information is crucial for the development of targeted interventions, the shaping of policy decisions, and ultimately the improvement of patient outcomes across the region.

## 111 **2. Methods**

112 The protocol for the present systematic review and meta-analysis was registered 113 prospectively on PROSPERO (registration number – CRD42024595654). The Preferred 114 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were 115 followed throughout the search and study selection process to ensure transparency and 116 completeness. Discrepancies between the registered protocol and research methodology are 117 reported in **Appendix 1**.

118

# 119 2.1. Data Sources and Search Strategy

A literature search was undertaken across multiple biomedical databases, including PubMed, Medline, Web of Science, and Scopus, to identify studies reporting 5-year survival estimates for breast cancer across African countries. The search was restricted to articles published from database inception to October 2024 to ensure the inclusion of the most recent data. We used the SPIDER framework (Sample, Phenomenon of Interest, Design, Evaluation, Research Type) to structure our search strategy as follows:

126

127 *Sample (S)*: Patients diagnosed with breast cancer in Africa.

- 128 *Phenomenon of Interest (PI):* 5-year survival estimates.
- 129 *Design (D):* Observational studies, retrospective and prospective.
- 130 *Evaluation (E):* 5-year survival rates and socio-demographic factors influencing survival.
- 131 *Research Type (R):* Quantitative studies that report survival rates.
- 132

We used a combination of author keywords and Medical Subject Headings (MeSH) terms such as "breast cancer," "five-year survival," "Africa," "Kaplan Meier," and "survival." To enhance the comprehensiveness of our search, we performed a citation search by examining the

reference lists of all relevant studies and published systematic reviews and meta-analyses 136 (Appendix 2). Given that literature from low-resource settings tends to be reported in non-137 indexed gray literature, we non-comprehensively and manually searched Google Scholar. The 138 139 search comprised of the string – ("survival") AND ("breast cancer") AND ("name of country") and restricted to availability of these terms in the title of the paper. This was done for all 54 140 countries in Africa to ensure that no data is missed from countries that were not included in 141 previous meta-analyses. No language restrictions were applied, but studies had to include an 142 English abstract. 143

144

## 145 **2.2. Study Selection**

Studies were imported into the Covidence software and duplicates were automatically 146 removed (except Google Scholar searches). EKK, AAE, JK, and SB independently screened the 147 titles and abstracts of all identified articles. Full-text articles were then retrieved for studies that 148 appeared to meet the inclusion criteria based on their abstracts. Studies were included if they 149 reported 5-year survival rates for breast cancer patients, were conducted within African 150 countries, provided sufficient data to calculate proportions, and were published in any language. 151 Studies that did not provide separate survival rates for breast cancer, or were editorials, 152 commentaries, randomized control trials or reviews without original data, were excluded. 153 Conference abstracts were included if no corresponding full-text paper was found. For full-text 154 155 screening, PDFs of the non-English articles were uploaded and translated using PDFSimpli (https://pdfsimpli.com/pdf-editor/translate-pdf/; accessed 09th November 2024). 156

Each study was carefully evaluated against the inclusion and exclusion criteria. Any 157 discrepancies between reviewers during the study selection process were resolved through 158 discussion with ABP and BAG. If consensus could not be reached, a third reviewer, NJ was 159 consulted to make the final decision. The study selection process was meticulously documented 160 using a PRISMA flow diagram to illustrate the number of records identified, screened, and 161 assessed for eligibility and inclusion. For Google Scholar searches, results were not considered 162 for inclusion in PRISMA flow diagram, primarily due to the non-comprehensive nature of our 163 search and unavailability of results for majority of countries. For countries with results, the full 164 texts were directly screened by NJ and EKK against the inclusion criteria and the final list of 165 included studies from other databases. No new studies were identified from Google Scholar. 166

167

## 168 **2.3. Data Extraction**

Data from eligible studies were independently extracted by two reviewers using a 169 standardized data extraction Excel form. Extraction was done in pairs by EKK and SB, ABP and 170 BAG, and AAE and JK. Extracted data included study characteristics such as authors, year of 171 publication, country, gender, region, race, median age, sample size, overall survival (OS), and 172 number of participants alive at the end of 5-year follow-up period (n). The country's Human 173 174 Development Index (HDI) values was classified according to its HDI ranking in 2022 [12]. Socio-demographic Index (SDI), a measure from the Global Burden of Disease collaboration, 175 was categorized into quantiles to provide a comprehensive understanding of the demographic 176 context [13]. We also extracted the survival rates using Webplotdigitizer v.4.5., following the 177 method described by Tierney et al. [14]. 178

To account for sex differences in our analysis, we categorized studies with mixed male and female participants based on a threshold criterion. Specifically, studies were classified under a specific sex group if one sex constituted at least 80% of the sample population. This cutoff was

selected to ensure that the overall survival outcomes would be predominantly driven by the 182 183 characteristics of the majority sex group, thereby reducing potential confounding effects from mixed-sex samples. This method, though implicitly employed by other studies [10,15], validates 184 its use in our work. Furthermore, we believe that such a methodological approach allows for a 185 more accurate representation of the primary variable of interest in the sex-specific survival 186 analysis. When necessary, corresponding authors were contacted to obtain additional information 187 or clarifications. Any discrepancies in data extraction were resolved through consultation with a 188 third reviewer, NJ. The extracted data were then reviewed and validated by the research team to 189 ensure accuracy and consistency. 190

191

# 192 2.4. Quality Assessment

The quality assessment of the included studies was adapted from the methodology 193 outlined by Ssentongo et al. (Appendix 3) [10]. This method was selected for its specificity to 194 breast cancer meta-analysis and its ability to provide numerical outcomes that can be used to 195 assess study-level covariates. The approach evaluates studies based on three primary criteria -196 detailed demographic information, stratified reporting of survival, and sample size. Each 197 198 criterion has a maximum score, with demographic information scoring up to 11 points, stratified reporting of survival up to 7 points, and sample size up to 6 points. The higher the number of 199 points, the better the quality of the assessed study. 200

201

# 202 **2.5. Data Analysis**

The survival rates were pooled using the random effects inverse variance method, 203 employing the "metaprop" function in the <meta> package of R v.4.4.0. Proportions were 204 transformed using the logit transformation, and the 95% confidence interval (CI) was based on 205 the Clopper-Pearson interval (exact binomial interval). To estimate heterogeneity variance, we 206 used the Restricted Maximum Likelihood (REML) method, which is more suitable for sub-207 groups involving a small number of studies, as the DerSimonian method can be misleading 208 [16,17]. Subgroup analyses were conducted based on geographic region (Northern, Eastern, 209 Central, Western, Southern Africa), patient sex and ethnicity, Human Development Index (HDI), 210 Social Development Index (SDI), individual countries, and year of publication. 211

Statistical heterogeneity was assessed using the I<sup>2</sup> statistic and Cochran's Q test. 212 Publication bias was evaluated with funnel plots and Egger's test, with adjustments made using 213 214 the fill and trim method. Additionally, a limit meta-analysis was conducted. Meta-regression analyses examined the influence of study-level covariates on survival outcomes. The <metafor> 215 and *<orchard>* packages were used for the meta-regression. A cumulative meta-analysis was 216 conducted to assess changes in survival rates in Africa over time. We compared our results to 217 previously reported estimates for Africa and other World Health Organization (WHO) regions 218 using one-sample Z test. 219

220

# 221 **3. Results**

A total of 3884 records were identified through a comprehensive search of four biomedical databases and citation searching. After a thorough screening of abstracts, titles, and full texts, 79 records were deemed eligible for inclusion (**Figure 1**) [18-96]. As some records presented data for multiple countries or demographics within a single record, we designated a reference as a "record", while each corresponding data was termed as a "study". Accordingly, we included 88 studies in the pooled meta-analysis. Similarly, 91 studies were analyzed for sex-

specific survival outcomes. Data from 27,559 individuals was pooled in our study, with a female-

- to-male ratio of 26,709 to 850 (97% to 3%), respectively. The articles were sourced from 22 of
- the 54 countries in Africa. Study and sampling characteristics are summarized in Appendix 4.



231

Figure 1. PRISMA flowchart. Flowchart showing the number of records identified, screened, and deemed eligible for pooled meta-analysis.

234

## 235 **3.1. Meta-analysis**

The overall pooled survival rate was 48% (95% CI: 43-53%), with high heterogeneity (I<sup>2</sup> 236 = 97.9%), indicating substantial variability among the included studies. Sub-group-wise, a 237 marginal discrepancy in survival rates was observed between the sexes, with females exhibiting a 238 slightly lower survival rate (48%) compared to males (51%), though this difference was not 239 240 statistically significant. However, a significant ethnic disparity was observed, with African nonblack patients exhibiting a higher survival rate (62%) compared to African black patients (38%). 241 Survival rates were also found to be significantly correlated with socioeconomic development. 242 Regions exhibiting higher human development index (HDI) levels demonstrated superior 243 outcomes, with high HDI regions exhibiting a 60% survival rate, medium HDI regions a 42% 244 survival rate, and low HDI regions a 37% survival rate. 245

A similar pattern was observed with the Socio-demographic Index (SDI), where high-246 middle SDI regions exhibited the highest survival rate (62%) and low SDI regions exhibited the 247 lowest (34%). Furthermore, it was observed that studies published prior to 2019 indicated a 248 higher survival rate (49%) than those conducted from 2019 onwards (44%). Although the impact 249 of the COVID-19 pandemic might be considered a contributing factor in this decline, we would 250 urge caution in this interpretation. The reported studies were conducted retrospectively, and the 251 year of publication may not be a reliable measure of the effect in question. This observed decline 252 has been explored and addressed in greater detail later in the paper. 253

Furthermore, considerable variability was observed across African regions, with Northern Africa having the highest survival rate (64%) and Western Africa having the lowest (32%). Country-specific analyses indicate that Mauritius (73%) and Namibia (70%) recorded the highest survival rates, whereas the Gambia (11%) had the lowest rates.

Variable	Studies	5-year S	urvival Rate (%) with 95% CI	l <sup>2</sup>	P <sub>hetero</sub>	Psubgroup
Patient Sex			1			
Male	15	51% (36-65%)		84.1	< 0.001	
Female	76	48% (42-54%)	-+-	98.2	< 0.001	0.730
Patient Ethnicity						
African Non-black	38	62% (56-68%)		97.0	< 0.001	
African Black	50	38% (32-45%)		96.2	< 0.001	< 0.001
Human Developmer	nt Index (HD	1)				
High	34	60% (54-67%)		97.7	< 0.001	
Medium	29	42% (33-53%)		95.7	< 0.001	< 0.001
Low	24	37% (29-47%)		97.2	< 0.001	
Socio-demographic	Index (SDI)					
Low	21	34% (26-44%)		97.0	< 0.001	
Low-middle	45	51% (43-59%)		98.0	< 0.001	
Middle	16	53% (43-63%)		93.3	< 0.001	< 0.001
High-middle	06	62% (54-70%)		77.8	< 0.001	
Year of Publication						
Before 2019	65	49% (43-56%)		97.9	< 0.001	
From 2019	23	44% (35-54%)		96.8	< 0.001	< 0.001
Continental African	Region					
Northern	37	64% (59-69%)		96.9	< 0.001	
Western	22	32% (23-42%)		94.3	< 0.001	
Eastern	20	39% (29-50%)		97.6	< 0.001	< 0.001
Southern	07	48% (31-66%)		94.8	< 0.001	
Central	02	37% (01-96%)		90.2	0.001	
Country (n = 22)						
Tunisia	10	56% (44-67%)		91.4	< 0.001	
Nigeria	12	28% (16-45%)		94.9	< 0.001	
Uganda	06	39% (21-60%)		92.1	< 0.001	
Egypt	14	69% (59-78%)		95.4	< 0.001	
South Africa	04	43% (14-77%)		97.1	< 0.001	
Libva	04	58% (53-63%)		00.0	0.760	
Gambia	02	11% (04-26%)		00.0	0.770	
Morocco	06	69% (65-73%)	-	37.6	0.160	
7imbabwe	02	49% (13-86%)		23.3	0.250	
Ethionia	07	34% (18-54%)		98.5	< 0.001	
Guinea	02	53% (12-90%)		66.5	0.080	
Cameroon	02	37% (01-96%)		90.2	0.001	< 0.001
Sudan	03	61% (15-94%)		95 3	< 0.001	
Ghana	02	44% (09-86%)		78.8	0.030	
Burking Faco	02	24% (0-100%)		03.7	< 0.001	
Konva	04	120 (00-0100 %)		95.7	< 0.001	
Algeria	01	45% (41-50%)		N/A	N/A	
Sevchelles	01	61% (51-70%)		N/A	N/A	
Namibia	01	70% (58-81%)		N/A	N/A	
Tanzania	01	22% (18-27%)		N/A	N/A	
Benin	01	49% (43-54%)		N/A	N/A	
Mauritius	01	73% (69-77%)	-	N/A	N/A	
Overall Pooled	88	48% (43-53%)	4	97.9	< 0.001	
		10/ 2				

259

258

Figure 2. Sub-group meta-analysis for 5-year breast cancer survival rates across Africa. The blue box represents the overall survival rate of the respective sub-groups, while the red box indicates the pooled overall survival rate. The horizontal lines traversing each box depict the corresponding confidence intervals.  $P_{hetero}$  represents the P value for heterogeneity test while  $P_{subgroup}$  indicates the P value for the test for subgroup analysis. I<sup>2</sup> represents the statistical heterogeneity (%) in the analysis. N/A – not applicable due to single study meta-analysis.

266

We next conducted a cumulative chronological meta-analysis to examine the evolution and trajectory of 5-year survival rates. The analysis, which commenced with Tabbane et al.,

(1977) [68] and concluded with Gnangnon et al., (2024) [83], revealed interesting trends. The 269 270 observed survival rates ranged from 15% to 50% between 1977 and 2024. The P values, which were calculated by comparing the observed effect with a previously reported null effect of 47%, 271 272 exhibited considerable variation. Among the included studies, only three demonstrated statistically significant results (P < 0.05) from this null effect. As the number of studies 273 increased, the overall survival rate rose and the confidence intervals narrowed, reflecting 274 enhanced precision in the cumulative estimate. However, since the early 2010s, the overall 275 survival rate has stabilized around 48-50%, with no discernible or predictable trend in the future. 276

277

Source	P-value	Tau2	Tau	12	Proportion (95% CI)	1722
Adding Tabbane et al.,1977 (k=1)	< .001				0.38 [0.34; 0.42]	_ +++ +
Adding Otu et al., 1989 (k=2)	.14	0.8181	0.9045	91%	0.25 [0.08; 0.55]	
Adding Ihekwaba et al.,1993 (k=3)	.02	1.0378	1.0187	92%	0.17 [0.06; 0.42]	- <u>-</u> ,
Adding Okobia and Osime,2001 (k=4)	.001	0.8373	0.9151	93%	0.15 [0.06; 0.32]	
Adding Ikpat et al.,2002 (k=5)	.10	2.0761	1.4409	96%	0.23 [0.08; 0.52]	
Adding Ben Ahmed et al.,2002 (k=6)	.13	1.8719	1.3682	96%	0.27 [0.11; 0.53]	
Adding Ben Dhiab et al.,2005 (k=7)	.21	1.8366	1.3552	96%	0.32 [0.14; 0.56]	
Adding Gondos et al.,2005 (k=8)	.18	1.5529	1.2462	95%	0.33 [0.17; 0.54]	
Adding Khanfir et al.,2006 (k=9)	.24	1.4422	1.2009	94%	0.35 [0.20; 0.55]	· · · · · · · · · · · · · · · · · · ·
Adding Ben Gobrane et al.,2007 (k=10)	.32	1.3713	1.1710	95%	0.38 [0.22; 0.56]	
Adding Gakwaya et al.,2008 (k=11)	.38	1.2566	1.1210	94%	0.40 [0.25; 0.56]	
Adding Taha et al.,2009 (k=12)	.39	1.1381	1.0668	94%	0.40 [0.27; 0.56]	
Adding Zeeneldin et al.,2009 (k=13)	.58	1.1647	1.0792	94%	0.43 [0.29; 0.58]	
Adding El-Habbash et al.,2009 (k=14)	.67	1.0908	1.0444	93%	0.44 [0.31; 0.58]	
Adding Basro and Apffelstaedt,2010 (k=15)	.47	1.1058	1.0516	94%	0.42 [0.29; 0.56]	
Adding Kene et al.,2010 (k=16)	.64	1.1172	1.0570	94%	0.44 [0.31; 0.57]	
Adding El Mongy et al.,2010 (k=17)	.94	1.4903	1.2208	98%	0.48 [0.33; 0.62]	
Adding Sankaranarayanan et al.,2010 (k=18)	.79	1.6048	1.2668	97%	0.45 [0.31; 0.60]	
Adding Sankaranarayanan et al. 2010 (k=19)	.79	1.5046	1.2266	97%	0.45 [0.32: 0.59]	
Adding Bourhafour et al. 2011 (k=20)	.89	1.4419	1.2008	97%	0.46 [0.33: 0.59]	
Adding Seedhom and Kamal 2011 (k=21)	.96	1.4104	1,1876	97%	0.47 [0.35: 0.60]	
Adding Elshafiev et al., 2011 (k=22)	.85	1.3615	1,1668	97%	0.48 [0.36: 0.61]	
Adding Chokunonga et al. 2011 (k=23)	82	12902	1 1359	97%	0 48 [0 37: 0 60]	_ <u> </u>
Adding Bah et al. 2011 (k=24)	.90	1.4137	1,1890	97%	0.46 [0.35: 0.58]	
Adding Wabinga et al. 2011 (k=25)	85	13529	1 1632	97%	0 46 [0 35: 0 58]	
Adding Abdalla et al. 2017 (k=26)	90	1 2955	1 1382	97%	0.46 [0.35: 0.57]	
Adding Abdalla of al. 2012 (k=20)	.50	12/55	1 1157	07%	0.47 [0.36: 0.57]	
Adding Mohammad et al. 2012 (k=28)	80	1 2527	1 1621	97%	0.48 [0.38: 0.59]	
Adding Kontalhardt at al. 2012 (k=20)	20	1 3051	1 1280	079/	0.40 [0.30, 0.59]	
Adding El Doshboshi and Abo Elnaga 2012 (k-20)	.//	1.2531	1 1196	9770	0.48 [0.38, 0.39]	
Adding El-Baradio et al. 2012 (k-24)	.75	1,2512	1 1013	9770	0.49 [0.39; 0.39]	- 8
Adding Khalifi at al. 2012 (K=31)	.05	1.2120	1.1012	97%	0.49 [0.39; 0.59]	
Adding Kneuti et al. 2012 (k=32)	.62	1.1695	1.0814	97%	0.49[0.40; 0.59]	
Adding Anmed et al.,2012 (k=33)	./5	1.1/53	1.0841	97%	0.49 [0.39; 0.58]	
Adding Mabula et al.,2012 (K=34)	.90	1.1859	1.0890	97%	0.48 [0.38; 0.57]	
Adding Ermiah et al.,2013 (k=35)	.83	1.1537	1.0741	97%	0.48 [0.39; 0.57]	
Adding Zeeneldin et al.,2013 (k=36)	.65	1.1901	1.0909	98%	0.49 [0.40; 0.58]	
Adding Bouzid et al.,2013 (k=37)	.56	1.1689	1.0812	98%	0.50 [0.41; 0.59]	
Adding Anele et al.,2014 (k=38)	.79	1.2631	1.1239	98%	0.48 [0.39; 0.57]	
Adding Kantelhardt et al.,2014 (k=39)	.79	1.2242	1.1064	98%	0.48 [0.39; 0.57]	
Adding Makanjuola et al.,2014 (k=40)	.91	1.2219	1.1054	98%	0.47 [0.39; 0.56]	
Adding Ayoade et al.,2014 (k=41)	.96	1.2238	1.1063	98%	0.47 [0.38; 0.55]	
Adding Galukande et al.,2015 (k=42)	.99	1.1899	1.0908	98%	0.47 [0.39; 0.55]	
Adding Aiad et al.,2015 (k=43)	.98	1.1592	1.0766	98%	0.47 [0.39; 0.55]	
Adding Traore et al.,2015 (k=44)	.93	1.1323	1.0641	98%	0.47 [0.39; 0.55]	— <u>—</u>
Adding Ben Abdelkrim et al.,2015 (k=45)	.78	1.1590	1.0766	98%	0.48 [0.40; 0.56]	- <del>0</del> -
Adding Kallel et al.,2015 (k=46)	.69	1.1422	1.0687	98%	0.49 [0.41; 0.57]	- <u>-</u>
Adding Ngowa et al. 2015 (k=47)	.77	1.1290	1.0626	98%	0.48 [0.40: 0.56]	
Adding Elhai et al.,2015 (k=48)	.81	1.1058	1.0516	98%	0.48 [0.40; 0.56]	- <u></u>
Adding Slaoui et al. 2016 (k=49)	.71	1.0983	1.0480	98%	0.48 [0.41: 0.56]	
Adding Samaka and Younes, 2016 (k=50)	.57	1,1173	1.0570	98%	0.49 [0.42: 0.57]	
Adding Derkagui et al. 2016 (k=51)	49	1,1107	1.0539	98%	0.50 [0.42: 0.57]	_ <u>_</u>
Adding Alaqui Slimani et al. 2016 (k=52)	42	1.0974	10476	98%	0 50 [0 43: 0 57]	
Adding Parag and Buccimazza 2016 (k=53)	37	1.0819	1.0401	98%	0.50 [0.43: 0.57]	
Adding Mensah et al. 2016 (k=54)	.36	1.0575	1.0284	98%	0.50 [0.43: 0.57]	
Adding Thomas et al. 2017 (k=55)	38	10382	10189	98%	0 50 0 43 0 57	
Adding Bogan et al. 2017 (k=56)	36	1.0168	1 0084	98%	0 50 10 43 0 571	
Adding Kaabia et al. 2017 (k=57)	43	1.0185	1 0092	98%	0 50 [0 43: 0 56]	_ <u>_</u>
Adding Rakkach at al. 2017 (k-59)	25	1.0216	1 0109	00%	0.50 [0.44: 0.57]	
Adding Cubasch et al. 2019 (k=50)	31	1.0210	1.0108	90%	0.50 [0.44, 0.57]	
Adding Ebor Schula at al 2018 (k=60)	42	1.0035	1.0010	00%	0.50 [0.44, 0.57]	
Adding Equad at al. 2010 (k=61)	.42	1.0270	1.0137	<b>70</b> /0	0.50 [0.43, 0.50]	
Adding Ismail at al. 2018 (k=61)	.42	0.0000	0.0055	00%	0.50 [0.43, 0.50]	6
Adding Zongo of al. 2018 (k=62)	20	0.9909	0.0964	00%	0.50 [0.43, 0.50]	
Adding Weiner et al. 2018 (k=64)	.30	1 0100	1 0050	90 /0	0.50 [0.44, 0.50]	
Adding Ergumo at al 2019 (k=65)	.52	1.0100	1.0030	90%	0.49 [0.43, 0.55]	8
Adding Soliman 2019 (k=66)	.45	0.0004	0.0022	0.00	0.49 [0.43; 0.50]	
Adding Solitian,2019 (k=60)	.40	0.9908	0.0054	90%	0.49 [0.43; 0.55]	
Adding Jako-Eru et al. 2020 (k=67)	.34	0.2906	0.9934	9076	0.49 [0.43; 0.33]	R
Adding Joko-Fru et al. 2020 (K=00)	.50	0.9703	0.9001	90%	0.49 [0.43; 0.35]	
Adding Joko-Fru et al.,2020 (k=69)	.50	0.9655	0.9826	98%	0.49 [0.43; 0.55]	
Adding Joko-Fru et al.,2020 (k=70)	.42	0.9666	0.9832	98%	0.49 [0.44; 0.55]	별
Adding Joko-Fru et al.,2020 (k=71)	.30	0.9623	0.9810	98%	0.50 [0.44; 0.56]	
Adding Joko-Fru et al.,2020 (k=72)	.40	0.9542	0.9768	98%	0.49 [0.44; 0.55]	
Adding Joko-Fru et al.,2020 (k=73)	.36	0.9420	0.9706	98%	0.50 [0.44; 0.55]	별
Adding Joko-Fru et al.,2020 (k=74)	.51	0.9884	0.9942	98%	0.49 [0.43; 0.55]	
Adding Joko-Fru et al.,2020 (k=75)	.52	0.9746	0.9872	98%	0.49 [0.43; 0.55]	별
Adding Fouhi et al.,2020 (k=76)	.51	0.9613	0.9805	98%	0.49 [0.43; 0.55]	받
Adding Abdalla Elhassan,2020 (k=77)	.41	0.9732	0.9865	98%	0.49 [0.44; 0.55]	
Adding zingue et al.,2021 (k=78)	.42	0.9593	0.9794	98%	0.49 [0.44; 0.55]	世
Adding Ali-Gombe et al.,2021 (k=79)	.45	0.9483	0.9738	98%	0.49 [0.44; 0.55]	
Adding Tiruneh et al.,2021 (k=80)	.52	0.9498	0.9746	98%	0.49 [0.43; 0.54]	
Adding Muddather et al.,2021 (k=81)	.47	0.9406	0.9698	98%	0.49 [0.44; 0.54]	
Adding Olasehinde et al.,2021 (k=82)	.48	0.9274	0.9630	98%	0.49 [0.44; 0.54]	
Adding Wambua et al.,2022 (k=83)	.43	0.9191	0.9587	98%	0.49 [0.44; 0.54]	
Adding Wuraola et al.,2022 (k=84)	.45	0.9072	0.9525	98%	0.49 [0.44; 0.54]	
Adding Some et al.,2022 (k=85)	.54	0.9154	0.9568	98%	0.49 [0.43; 0.54]	-
Adding Traore et al.,2022 (k=86)	.53	0.9026	0.9501	98%	0.49 [0.44; 0.54]	
Adding Matheka et al.,2023 (k=87)	.69	0.9413	0.9702	98%	0.48 [0.43; 0.53]	-8-
Adding Gnangnon et al.,2024 (k=88)	.68	0.9287	0.9637	98%	0.48 [0.43; 0.53]	- <del>0</del> -
Total	.68	0.9287	0.9637	98%	0.48 [0.43; 0.53]	$\diamond$
					r	
					0	0.2 0.4 0.6 0.8

278

Figure 3. Cumulative meta-analysis for 5-year survival rates in Africa, adding studies in chronological order. The blue box represents the overall survival rate of the respective study, while the

horizontal lines traversing each box depict the corresponding confidence intervals. Tau, Tau<sup>2</sup>, and  $I^2$ represent the different measures of statistical heterogeneity in the pooled estimate.

283

#### 284 **3.2. Meta-regression**

Meta-regression analyses were performed to evaluate the influence of different factors on 5-year survival rates. Among the continuous factors, mean years of schooling (MYS) and quality score (QS) of the included studies were both found to have significant influences (P = 0.001 and 0.023, respectively). MYS and QS accounted for 10.85% and 4.80% of the heterogeneity in survival, respectively. Each additional year of mean schooling was associated with a 2.41% (95% CI: 0.98-3.84%) increase in 5-year survival. Similarly, each 1-point increase in quality score was associated with a 1.39% (95% CI: 0.19-2.59%) increase in survival (**Figure 4**).





293

Figure 4. Bubble plots for the relationship between mean years of schooling (MYS) and quality score (QS) of the included studies with the 5-year survival rate of breast cancer patients. Each point represents a study, with the size of the points indicating the precision (1/standard error) of the data. The solid black line represents the regression line, the dashed lines indicate the 95% confidence intervals, and the dotted lines show the prediction intervals.

299

Additional analyses for categorical predictors revealed significant associations for survival rates with country, patient ethnicity, African continental regions, HDI quartiles, and SDI quintiles, indicating that survival rates are significantly influenced by these factors. However, no significant associations were found for patient sex and year of publication (**Figure 5**).



Figure 5. Orchard plots for the meta-regression analyses of the 5-year survival rate and categorical predictors. The plots show the pooled survival rate (trunk), 95% confidence intervals (branches), and prediction intervals (twigs). Bubble sizes indicate precision (1/standard error) of each study, with larger points representing higher precision.

#### **309 3.3. Publication Bias and Small Study Effects**

We used the Egger's test to assess funnel plot asymmetry. The test result indicated significant asymmetry and was considered suggestive of potential publication bias (t = -3.15, P = 0.002. The bias estimate was -4.007 with a standard error (SE) of 1.271. Next, the trim-and-fill test was performed which included 114 studies, with 26 hypothetical studies added to adjust for bias (**Figure 6**). The adjusted 5-year survival rate using the random effects model was 62% (95% CI: 55-67%), with a prediction interval ranging from 10-96%. This adjustment indicates that the true effect size is likely to be within this broader range, accounting for potential missing studies.

317



318

Figure 6. Funnel plots for assessing publication bias in studies reporting breast cancer survival rates. Standard funnel plot for 88 studies (panel A); contour-enhanced funnel plot for 88 studies (panel B); Trim-and-fill funnel plot with 26 hypothetical studies (white dots) added to 88 studies (gray dots; panel C); and Limit meta-analysis funnel plot showing increasing bias with standard error. Gray diamond shows the adjusted average effect when standard error is zero.

324

The analysis still quantified substantial heterogeneity among the included studies, with a tau-square ( $\tau^2$ ) value of 1.837 (95% CI: 1.446-2.509). The I<sup>2</sup> statistic was observed to be extremely high at 98.4% (95% CI: 98.3-98.5%), indicating that nearly all the variability in effect estimates is due to heterogeneity rather than random chance. The limit meta-analysis, on the other hand, provided a 5-year survival estimate of 52% (95% CI: 45-59%).

Heterogeneity statistics indicated a  $\tau^2$  value of 0.9287, with an I<sup>2</sup> of 97.9% (95% CI: 97.7-98.1%), reflecting substantial heterogeneity among the studies. Additionally, the test for smallstudy effects demonstrated Q-Q' of 430.25 (P < 0.0001), suggesting the presence of small-study

effects. The residual heterogeneity test produced Q' = 3719.79 (P < 0.0001), indicating 333 significant residual heterogeneity beyond small-study effects. 334

335

349

#### 3.4. Comparison with 2018 African Estimates 336

A previous meta-analysis, which included literature up to October 2018, identified 54 337 eligible records from 14 countries [10]. The authors reported a pooled overall 5-year survival rate 338 of 53% (95% CI: 46-60%), while our own findings indicated an estimate of 48% (95% CI: 43-339 53%). We conducted a one-sample Z-test for proportions to compare the two estimates and found 340 no statistical significance (P = 0.071). Nonetheless, given that our estimates indicated a lower 341 survival rate than previously reported, we explored the cause for this observation. 342

At first, we postulated that our larger and more diverse data set, comprising 22 countries, 343 could have yielded a more precise estimate. To explore this, we subset our data into two groups, 344 one part with data from same 14 countries as reported from 2018 meta-analysis and the other part 345 with data from 8 new countries (Figure 7). The forest plot demonstrated that the estimate 346 derived from the former group remained inferior to the estimates reported by the 2018 study 347 (47% vs 53%). 348

2018 - 56% (48-65%) 2024 - 56% (44-67%) 2018 - 45% (41-50%) 2024 - 45% (41-50%) 2018 - 59% (53-64%) 2024 - 58% (53-63%) 2018 - 70% (64-76%) Forest plot for effect of new countries in our dataset 2024 - 69% (59-78%) Proportion (95% CI) 2018 - 70% (67-73%) 2024 - 69% (65-73%) Source Africa\_14 countries 0.67 (0.67-0.53) Ð **E 2024 - 61% (15-94%)** Prediction interval [0.11; 0.87] Heterogeneity:  $\chi^2_{72}$  = 3842.39 (P < .001), 1<sup>2</sup> = 98% t<sup>2</sup> = 0.992 Africa\_8 countries 2018 - 50% (36-64%) 2024 - 34% (0-100%) 2018 - 12% (04-20%) 2024 - 11% (04-26%) = 52 [0 /1:0 62 Prediction interva [0.15; 0.87] 2018 - 33% (14-<mark>51%)</mark> 2024 - 28% (16<mark>-45%)</mark> 2018 - 32% (14-49%) 2024 - 34% (18-54%) meity:  $\chi^2_{14}$  = 307.64 (P < .001), I<sup>2</sup> = 95%t<sup>2</sup> = 0.672 0 48 (0.43; 0.53) Prediction interval [0.12; 0.86] 0.7 0.4 0.6 0.8 meity:  $\chi^2_{e_7}$  = 4150.05 (P < .001), 1<sup>2</sup> = 98%,  $\tau^2$  = 0.928 2018 - 58% (50-66%) 2024 - 53% (12-90%) 2024 - 37% (01-96%) 2024 - 42% (09-84% Forest plot for effect of references excluded in 2018 estimates 2018 - 52% (46-57%) 2024 - 39% (21-60%) 2018 - 40% (34-46%) . Proportion (95% CI) Source 2024 - 44% (09-86%) Ē Z 2024 - 61% (51-70%) Prediction interval [0.14; 0.89] **1 2024 - 49% (43-54%** eity: x<sup>2</sup><sub>65</sub> = 2771.29 (P < .001), I<sup>2</sup> = 98% t<sup>2</sup> Heteroger 0.32 (0.21; 0.47) 2018 - 22% (18-26%) 2024 - 22% (18-27%) Prediction interva [0.04: 0.83] nity: x<sup>2</sup> = 188.48 (P < .001), 1<sup>2</sup> = 95%T<sup>2</sup> = 0.9247 Survival Rate (%) 0.49 [0.43: 0.56] 0 [0.11; 0.88] Prediction interval -2024 - 49% (13-86% 60 0.2 0.4 0.6 0.8 rogeneity:  $\chi^2_{c_0}$  = 3106.12 (P < .001), I<sup>2</sup> = 98%,  $\tau^2$  = 1.004 Test for subg ces: x<sup>2</sup> = 6.02 (P = .01 5-year Survival Rate 40 2024 - 70% (58-81%) 20 = 2024 - 73% (69-77%) 2018 - 48% (18-79%) 2024 - 43% (14-77%)

Figure 7. Comparison of our current 5-year survival estimates with the previous 2018 estimates. A territorial map of continental Africa is shown (on the left) with 5-year survival estimates and 95% confidence interval from 2018 and 2024. The survival estimates have been rounded off to the nearest whole number. Two forest plots are shown (on the right) that were used to estimate the effect of addition of eight new countries in our 2024 estimates and the effect of missed/excluded references in the 2018 355 estimates. 356

357

358 Subsequently, we cross-referenced the meta-analyzed studies from the previous work and those from the present study. We observed that the authors had not included 10 studies that were 359

published before 2018 and met their inclusion criteria, potentially attributable to the limited
number of databases they searched (Medline, Embase, and Cochrane Library). These studies
were from Uganda, Gambia, Ghana, Ethiopia, Nigeria, Cameroon, Sudan, and Zimbabwe.
Inclusion of these 10 studies yielded an estimated 5-year survival rate of 49% (95% CI: 43-56%;
Figure 7), which is in close alignment with our pooled overall survival rate of 48%.

This decrease observed in 2018 estimates was expected since the studies not included 365 were primarily from low and low-middle SDI countries. In our view, these findings have two 366 broader public health ramifications. First, although not significantly different from our estimates, 367 the previously reported survival estimates appear to be inflated due to incomplete catch from the 368 investigated biomedical databases, highlighting the need for a comprehensive search strategy. 369 Second, as observed with our cumulative meta-analysis, the 5-year survival rate has somewhat 370 stagnated in Africa. Apart from Ghana, all other countries either observed a modest decrease or 371 no change in 5-year survival estimates (Figure 7). Burkina Faso and Uganda experienced the 372 largest declines, although the one-sample z-test for proportions was not significant (P = 0.268) 373 and 0.195, respectively). 374

375

#### 376 **3.5.** Comparison with Global Estimates among Female Patients

We also conducted a generic Google Scholar and PubMed search to look for pooled 5year survival rates for breast cancer patients. The search was specifically designed to retrieve systematic reviews and meta-analyses published in the last decade that included data from multiple countries and had pooled the results based on either regional grouping, WHO regions, or at the continent level. Consequently, three such studies were identified for comparison [97-99]. Given that these studies reported survival rates exclusively for female patients, they were compared with our estimates derived from the female subset only (**Figure 8**).



Figure 8. Comparison of our current 5-year survival estimates with the previously reported global
 estimates. Forest plot showing the pooled meta-analyzed overall 5-year survival rate with 95%
 confidence interval for female patients with breast cancer across different regions. WHO – World Health
 Organization; PAHO – Pan American Health Organization; WPRO – Western Pacific Region; SEARO –
 South-East Asia Region; EURO – European Region; EMRO – Eastern Mediterranean Region; AFRO –
 African Region; ASEAN – Association of Southeast Asian Nations.

#### 392

A comparative analysis of five-year survival rates for female patients across different regions revealed significant differences between our 2024 estimates and previously reported estimates from all regions (one-sample Z test P < 0.001), except for the WHO SEARO region (one-sample Z test P = 0.469). In 2017, the WHO WPRO and PAHO regions recorded the highest global survival rates of 76% and 75%, respectively. Similarly, the WHO EURO and WHO EMRO regions reported high survival rates of 74% and 71%, respectively.

Although the survival rate in the WHO SEARO region was slightly higher than our 2024 estimates, there is clearly room for improvement in both regions. Notably, the estimates from the WHO AFRO region, based on just four studies, reported a much lower survival rate of 28% in 2017. Upon subsetting and analyzing the results for female patients from WHO AFRO countries (48 studies; 17 countries), we observed a 5-year survival rate of 38% (95% CI: 32-44%). This indicates a considerable improvement in the WHO AFRO region's survival rate by 2024. Despite this progress, the survival rate remains substantially lower than in other WHO regions.

#### 406 407 **4. Discussion**

408 Our meta-analysis of 5-year survival rates for breast cancer patients in Africa offers 409 comprehensive insights into the current state of clinical outcomes across the continent. We 410 underscore the considerable disparities in survival rates across different regions and socio-411 economic contexts. The overall survival rate of 48% in Africa is markedly lower than those 412 reported in high-income countries, where survival rates frequently exceed 70-80% [97-99].

The sex-stratified analysis indicated no differences in survival rates between male and 413 female patients, suggesting that both genders encounter considerable challenges in the context of 414 early diagnostics and timely and effective treatment. In their study, Gómez-Raposo et al., found 415 that when age is accounted, breast cancer survival rates are similar for both males and females 416 [100]. Others have also reported similar findings when the cohorts were age-, region-, stage-, 417 and/or propensity-matched [101-104]. Nonetheless, the marginally higher survival rate observed 418 in males is interesting, as literature seems to suggest a worse prognosis for male breast cancer 419 patients. The lower survival rate observed in males has been suggested due to males having a 420 greater likelihood of being diagnosed at an older age, a higher prevalence of advanced disease 421 stages, and a tendency to adhere less strictly to treatment regimens [105]. Furthermore, the issue 422 is compounded by a lack of awareness and the absence of targeted screening programs for male 423 424 patients.

In the context of our study, data were available for male patients only from nine countries 425 in Africa. The rarity of male breast cancer surveillance and reporting may have resulted in the 426 inclusion of smaller, non-representative cohorts, thereby influencing the observed outcomes. 427 Furthermore, our methodological approach of categorizing studies based on a threshold criterion 428 429 (>80% of one sex) may also contribute to this observation. Finally, it may also be due to the 430 absence of triple-negative cases in the male cohort, suggesting that certain aggressive subtypes are less common among African men [106]. This absence of aggressive difficult-to-manage 431 phenotypes could influence and contribute to the observed higher survival rates. 432

Furthermore, African black women are more likely to be diagnosed with aggressive subtypes of breast cancer, such as triple-negative breast cancer (TNBC) [105,107]. TNBC is characterized by the absence of estrogen, progesterone, and HER2 receptors, which renders it more challenging to treat and is associated with a poorer prognosis [108-109]. The *ANKLE1* gene, which confers protection against TNBC, was found to be less prevalent in African

American women compared to white women of European descent [110]. Moreover, African American women with a mutation in the Duffy (*DARC*) gene, which is involved in the inflammatory response, have an elevated risk of developing TNBC [110].

441 Northern Africa, with its relatively high survival rates, benefits from a more robust healthcare infrastructure, more efficacious screening programs, and greater public awareness 442 about breast cancer. It is frequently the case that countries in this region are ranked high on HDI 443 and SDI evaluations [12-13]. Conversely, the lowest survival rates are observed in Western 444 Africa, which highlights the necessity for significant investments in healthcare services and 445 resource allocation. A country-specific analysis revealed significant contrasts, with Mauritius 446 recording the highest survival rate and Gambia having the lowest. These discrepancies may be 447 attributable to discrepancies in healthcare systems, the availability of cancer treatment facilities, 448 and national and international health partnerships and policies. 449

For example, in Mauritius, healthcare is regarded as a fundamental human right, with free 450 public health services for primary care being made available. Every household is situated within 451 three miles of a primary care provider, thereby ensuring accessible medical care for all. Active 452 investments are being made by the Ministry of Health and Wellness to construct a national 453 cancer hospital, while upgrading facilities at regional hospitals to ensure that cancer treatment is 454 provided free of charge to all citizens [111]. In contrast, the availability of facilities for breast 455 cancer screening, diagnosis, and treatment in Gambia is limited. Many of the diagnostic and care 456 457 centers are located at distances ranging from 10 to 45 kilometers from patients' residences. Consequently, nearly half of the Gambian population lacks access to pathologic diagnosis and 458 surgical management of breast cancer within these distance thresholds [112]. In other countries 459 with high overall breast cancer survival rates, such as Sevchelles and Namibia, which have 460 higher HDI values, the density of healthcare professionals (HCPs) per 1,000 population exceeds 461 the United Nations Sustainable Development Goals (SDG) density target of 4.45 HCPs per 1,000 462 population. Furthermore, these countries maintain healthcare quality ratings above 80% [113]. 463

A comparison of the 2024 estimates with the adjusted 2018 estimate and the findings 464 from our cumulative meta-analysis indicates a stagnation of survival rates around 48-49% over 465 time. This may be attributed to several factors. The healthcare infrastructure across many African 466 countries remains underdeveloped, with the availability of essential diagnostic tools and 467 advanced treatment options remaining constrained, particularly in rural and low-resource settings 468 [114]. This inadequacy results in delayed diagnoses and suboptimal treatment outcomes. 469 Socioeconomic and cultural mistrust in Western medicine, in conjunction with pervasive poverty 470 and economic disparities, impede the capacity of patients to access essential healthcare services 471 at a reasonable cost [115-116]. Traditional beliefs and stigma associated with cancer can act as a 472 deterrent for individuals seeking medical care [117-118]. Despite the importance of efforts to 473 raise awareness and educate the population about the significance of early detection and 474 treatment, initiatives have thus far proven inadequate in terms of both scope and impact. 475

476 Systemic issues, including political instability and corruption, serve to further exacerbate 477 these challenges, impeding the implementation of cancer care programs [119]. Ultimately, 478 inadequate financial resources have an adverse ripple effect throughout the healthcare system, 479 from the unavailability of essential medications to the lack of sufficient training for HCPs, 480 perpetuating a vicious cycle of inadequate care and poor patient outcomes. Our observations also 481 highlight that sustained improvements in particular regions or countries are insufficient to 482 significantly alter the overall continental survival rate. The considerable heterogeneity observed

in the studies highlights the uneven distribution of healthcare resources and the variable qualityof care across different countries and regions.

Another notable finding was the positive correlation between mean years of schooling 485 (MYS) and breast cancer survival rates. Education plays a crucial role in enhancing health 486 outcomes by fostering health literacy, which provides for greater awareness of breast cancer 487 symptoms, the significance of early detection, and adherence to treatment regimens. Higher 488 levels of educational attainment afford patients the ability to navigate the healthcare system with 489 greater confidence and to make more informed decisions regarding their care. Furthermore, the 490 analysis underscores the influence of study quality on the reported survival rates, indicating that 491 higher-quality studies are associated with more favorable survival outcomes. This highlights the 492 necessity of rigorous study design and adherence to methodological standards to produce reliable 493 and accurate data. The quality of the studies included in the meta-analysis is reflective of the 494 variability in healthcare infrastructure, research funding, and expertise across different regions. 495

It is hence necessary to improve the caliber of research conducted in resource-limited 496 settings to generate evidence-based unbiased data and subsequently inform policy and practice. 497 The observed heterogeneity in survival rates is significantly influenced by region, country, race, 498 499 SDI, and HDI. This indicates that geographical and socio-economic factors exert a more pronounced influence on breast cancer outcomes in Africa than temporal trends or gender or 500 ethnicity. The evidence of significant publication bias, as indicated by Egger's test, suggests that 501 502 the reported survival rates may be overestimated due to the under-reporting of smaller studies with less favorable outcomes. 503

504

## 505 4.1. Limitations

While we followed a comprehensive protocol, there are several methodological 506 limitations that warrant consideration. The substantial heterogeneity among the included studies 507 indicates significant variability in survival rates, likely due to differences in study design, 508 population characteristics, and healthcare systems, complicating the generalization of results 509 across the continent. The presence of publication bias suggests that smaller studies might be 510 under-represented, potentially skewing the overall survival rate estimate despite adjustments 511 using the trim and fill method. Additionally, the analysis included studies from only 22 out of 54 512 African countries, limiting the representativeness of the findings and potentially overlooking 513 514 variations in survival rates in countries with no available data.

The reliance on published studies means that the quality and accuracy of the data are 515 contingent on the methodologies and reporting standards of the original research, introducing 516 inconsistencies. For instance, our approach for classification of studies based on patient sex does 517 not fully account for the nuanced effects of sex on breast cancer outcomes and could lead to an 518 over-estimation or under-estimation of survival rates for each sex. Additionally, while this 519 threshold ensures the majority sex group's characteristics predominantly drive the outcomes, it 520 521 highlights the necessity for further research to comprehensively disaggregate, record, and report data by sex. Another crucial disadvantage of reporting inconsistencies is that tumor 522 characteristics (staging, TNM classification, histological classification, localization, primary 523 tumor/metastasis) and clinically relevant parameters (patient age, treatment modality, follow-up 524 duration, quality of life outcomes) cannot be compared and pooled together. 525

526 Such limitations have been reported by previous global meta-analytical studies as well 527 where authors reported that data from low- and middle-income countries such as those in Africa 528 and Asia had >50% of patients with unknown breast cancer stages to report [6]. Furthermore,

assessment of tumor staging should be done using both clinical and radiological methods. However, a meta-analysis for Sub-Saharan African countries noted that < 25% of the studies reported the staging methods used with a few studies relying only on clinical assessment for staging [120]. Finally, socio-economic factors such as income and access to healthcare, which significantly impact patient outcomes, were not fully accounted for in the analysis. Addressing these limitations in future studies will enhance the accuracy and reliability of the findings, contributing to better-informed healthcare policies and interventions.

536

# 537 4.2. Recommendations based on current estimates

We reiterate the longstanding and urgent necessity of implementing targeted healthcare 538 policies to address the considerable regional disparities that are prevalent among African 539 countries. The observed correlation between higher survival rates and countries with a high HDI, 540 MYS, and SDI underscores the pivotal role of robust healthcare infrastructure, education, and 541 socio-economic development in enhancing cancer care. It is incumbent upon policymakers to 542 prioritize the allocation of resources to regions with the lowest survival rates, such as Western 543 Africa, and to invest in the development of healthcare facilities, diagnostic tools, and treatment 544 centers. Furthermore, it is crucial to enhance the training of HCPs in oncology, molecular 545 diagnostics, and palliative care. Implementing culturally sensitive public health campaigns, 546 adopting universal healthcare, and expanding insurance coverage to include cancer treatment are 547 548 essential steps.

The considerable heterogeneity and publication bias identified in our meta-analysis underscores the need for more comprehensive and high-quality record keeping and research, including the establishment of national cancer registries. International collaboration and partnerships with global health organizations can facilitate the transfer of knowledge and the allocation of funding for improvements in cancer care. There is a need to develop and implement an Africa-wide public health framework for the development of targeted strategies that address the specific needs and challenges of different regions and populations in Africa.

556

# 557 **5.** Conclusions

558 Our findings highlight the significant regional disparities in breast cancer survival rates across the African continent, reinforcing the urgent and sustained need for targeted health 559 560 interventions. The substantial heterogeneity among studies reflects the variability in the quality 561 of and access to health care across countries. The higher survival rates in countries with high HDI and SDI values underscore the importance of robust health systems and socioeconomic 562 development in improving survival. Gender differences in survival were found not to be a 563 covariate, highlighting the importance of controlling for other clinical and socio-demographic 564 factors. These findings provide a roadmap for developing effective cancer screening programs 565 and health policies, including implementation of uniform reporting standards and establishment 566 567 of national cancer registries, to improve breast cancer surveillance, monitoring, and survival rates across the continent. 568

569

# 570 6. Declarations

- a. Conflicts of interest None to declare.
- **b.** Funding None to declare.
- 574

## 575 **c.** Ethical approval – Not applicable.

- **d. Data Availability** All data generated is presented in the manuscript and appendices.
   Clarifications on methodology and requests for the R code can be directed to the corresponding authors.
- **e. Informed Consent** Not applicable.
- **f.** Acknowledgements None to declare.

g. Author contributions – ABP and NJ conceptualized the present study. Data curation, 585 collection, and screening was done by ABP, EKK, AGB, JK, AAE, BS, IN, and BOO 586 with inputs and validation from NJ. Methodology, investigations, visualizations, and 587 formal analysis were done by EKK and NJ. Software and code were maintained by EKK 588 and NJ. Project administration and supervision was done by ABP and NJ. Data validation 589 was done by EKK and NJ. The original draft was prepared by EKK, JK, ABP, and NJ 590 while all authors were involved in revising the manuscript. All authors have read the 591 592 manuscript and agreed on its contents for publication.

## 594 7. References

576

580

582

584

- Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol.
   2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID:
   34905391; PMCID: PMC8822551.
- Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, et al. The Lancet Breast Cancer Commission. Lancet. 2024 May 11;403(10439):1895-1950. doi: 10.1016/S0140-6736(24)00747-5. Epub 2024 Apr 15. PMID: 38636533.
- Sha R, Kong XM, Li XY, Wang YB. Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease
  Study 2021. Biomark Res. 2024 Aug 26;12(1):87. doi: 10.1186/s40364-024-00631-8. PMID: 39183342; PMCID: PMC11346191.
- 4. Testa U, Castelli G, Pelosi E. Breast Cancer: A Molecularly Heterogenous Disease Needing
  Subtype-Specific Treatments. Med Sci (Basel). 2020 Mar 23;8(1):18. doi:
  10.3390/medsci8010018. PMID: 32210163; PMCID: PMC7151639.
- 5. Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021 Aug 1;321(2):C343-C354. doi: 10.1152/ajpcell.00109.2021. Epub 2021 Jun 30. PMID: 34191627; PMCID: PMC8424677.
- 6. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, Vignat J, Znaor A, et al. Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024 Jan 1;10(1):71-78. doi: 10.1001/jamaoncol.2023.4837. PMID: 37943547; PMCID: PMC10636649.
- 615 7. Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for
  616 breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob
  617 Health. 2018 Aug;6(8):e885-e893. doi: 10.1016/S2214-109X(18)30257-2. PMID: 30012269;
  618 PMCID: PMC6214657.

- 8. Anyigba CA, Awandare GA, Paemka L. Breast cancer in sub-Saharan Africa: The current state
  and uncertain future. Exp Biol Med (Maywood). 2021 Jun;246(12):1377-1387. doi:
  10.1177/15353702211006047. Epub 2021 Apr 29. PMID: 33926257; PMCID: PMC8243219.
- Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, et al.
  Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022
  Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2. PMID: 36084384; PMCID:
  PMC9465273.
- 10. Ssentongo P, Lewcun JA, Candela X, Ssentongo AE, Kwon EG, Ba DM, Oh JS, Amponsah-Manu
  F, et al. Regional, racial, gender, and tumor biology disparities in breast cancer survival rates in
  Africa: A systematic review and meta-analysis. PLoS One. 2019 Nov 21;14(11):e0225039. doi:
  10.1371/journal.pone.0225039. PMID: 31751359; PMCID: PMC6872165.
- 11. Lakens D, Hilgard J, Staaks J. On the reproducibility of meta-analyses: six practical recommendations. BMC Psychol. 2016 May 31;4(1):24. doi: 10.1186/s40359-016-0126-3. PMID: 27241618; PMCID: PMC4886411.
- 633 12. United Nations Development Programme (UNDP). Human Development Reports: Human
   634 Development Index (HDI). 2024 [online]. Available from <u>https://hdr.undp.org/data-center/human-</u>
   635 <u>development-index#/indicies/HDI</u> (accessed 1st November 2024).
- 13. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 636 2021) Socio-Demographic Index (SDI) 1950-2021. Seattle, United States of America: Institute 637 Metrics Evaluation (IHME), 2024 638 for Health and [online]. Available from https://ghdx.healthdata.org/record/global-burden-disease-study-2021-gbd-2021-socio-639 demographic-index-sdi-1950%E2%80%932021 (Accessed 1st November 2024). 640
- 14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating
  summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16. doi: 10.1186/1745-62158-16. PMID: 17555582; PMCID: PMC1920534.
- Limenih MA, Mekonnen EG, Birhanu F, Jima BR, Sisay BG, Kassahun EA, Hassen HY. Survival
  Patterns Among Patients With Breast Cancer in Sub-Saharan Africa: A Systematic Review and
  Meta-Analysis. JAMA Netw Open. 2024 May 1;7(5):e2410260. doi:
  10.1001/jamanetworkopen.2024.10260. PMID: 38743426; PMCID: PMC11094564.
- 16. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, Viechtbauer W,
  Simmonds M. A comparison of heterogeneity variance estimators in simulated random-effects
  meta-analyses. Res Synth Methods. 2019 Mar;10(1):83-98. doi: 10.1002/jrsm.1316. Epub 2018
  Sep 6. PMID: 30067315.
- 17. Tanriver-Ayder E, Faes C, van de Casteele T, McCann SK, Macleod MR. Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research. BMJ Open Sci. 2021 Feb 25;5(1):e100074. doi: 10.1136/bmjos-2020-100074.
  PMID: 35047696; PMCID: PMC8647574.
- 656 18. Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at a tertiary hospital in
  657 sub-Saharan Africa: a cohort study. World J Surg Oncol. 2015 Jul 19;13:220. doi:
  658 10.1186/s12957-015-0632-4. PMID: 26187151; PMCID: PMC4506617.
- Gakwaya A, Kigula-Mugambe JB, Kavuma A, Luwaga A, Fualal J, Jombwe J, Galukande M,
  Kanyike D. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer.
  2008 Jul 8;99(1):63-7. doi: 10.1038/sj.bjc.6604435. Epub 2008 Jun 24. PMID: 18577991;
  PMCID: PMC2453032.
- 20. Thomas AS, Kidwell KM, Oppong JK, Adjei EK, Osei-Bonsu E, Boahene A, Jiggae E, Gyan K,
  Merajver SD. Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer

665		Registries in Low- and Middle-Income Countries. J Glob Oncol. 2017 Dec;3(6):765-772. doi:
666		10.1200/JGO.2016.006098. Epub 2017 Mar 27. PMID: 29244986; PMCID: PMC5735963.
667	21.	Anele AA, Bowling M, Eckert GJ, Gonzalez E, Kipfer H, Sauder C. Treatment of Breast Cancer:
668		Imo State Nigeria Versus Indiana, USA Women - Comparative Analytic Study. J West Afr Coll
669		Surg. 2014 Oct-Dec;4(4):39-69. PMID: 27182510; PMCID: PMC4866729.
670	22.	Cubasch H, Dickens C, Joffe M, Duarte R, Murugan N, Tsai Chih M, Moodley K, Sharma V,
671		Ayeni O, Jacobson JS, Neugut AI, McCormack V, Ruff P. Breast cancer survival in Soweto,
672		Johannesburg, South Africa: A receptor-defined cohort of women diagnosed from 2009 to 11.
673		Cancer Epidemiol. 2018 Feb;52:120-127. doi: 10.1016/j.canep.2017.12.007. Epub 2018 Jan 4.
674		PMID: 29306221: PMCID: PMC6127863.
675	23.	Eber-Schulz P, Tariku W, Reibold C, Addissie A, Wickenhauser C, Fathke C, Hauptmann S, Jemal
676		A, Thomssen C, Kantelhardt EJ. Survival of breast cancer patients in rural Ethiopia. Breast
677		Cancer Res Treat. 2018 Jul;170(1):111-118. doi: 10.1007/s10549-018-4724-z. Epub 2018 Feb 26.
678		PMID: 29479644.
679	24.	Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A, Avnalem A, Wondemagegnehu T,
680		Ersumo T, et al. Breast cancer survival in Ethiopia: a cohort study of 1.070 women. Int J Cancer.
681		2014 Aug 1:135(3):702-9. doi: 10.1002/jic.28691. Epub 2014 Jan 10. PMID: 24375396.
682	25.	Makaniuola SB. Popoola AO. Oludara MA. Radiation therapy: a major factor in the five-year
683		survival analysis of women with breast cancer in Lagos, Nigeria, Radiother Oncol. 2014
684		May:111(2):321-6. doi: 10.1016/i.radonc.2014.03.013. Epub 2014 Apr 17. PMID: 24746579.
685	26.	Kene TS, Odigie VI, Yusufu LM, Yusuf BO, Shehu SM, Kase JT, Pattern of presentation and
686		survival of breast cancer in a teaching hospital in north Western Nigeria. Oman Med J. 2010
687		Apr:25(2):104-7. doi: 10.5001/omi.2010.29. PMID: 22125710; PMCID: PMC3215495.
688	27.	Ikpat OF, Ndoma-Egba R, Collan Y. Influence of age and prognosis of breast cancer in Nigeria.
689		East Afr Med J. 2002 Dec:79(12):651-7. doi: 10.4314/eami.v79i12.8673. PMID: 12678449.
690	28.	Souad H. Zahia F. Abdelhak L. Karima S. Dalila S. Noureddine A. Descriptive study of triple
691		negative breast cancer in Eastern Algeria. Pan Afr Med J. 2018 Jan 18:29:45. doi:
692		10.11604/pamj.2018.29.45.12523. PMID: 29875927; PMCID: PMC5987100.
693	29.	Ismail A, El-Awady R, Mohamed G, Hussein M, Ramadan SS. Prognostic Significance of Serum
694		Vitamin D Levels in Egyptian Females with Breast Cancer. Asian Pac J Cancer Prev. 2018 Feb
695		26;19(2):571-576. doi: 10.22034/APJCP.2018.19.2.571. PMID: 29481024; PMCID:
696		PMC5980952.
697	30.	Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. The role
698		of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt:
699		possible link to disease early lesion. BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-
700		017-3283-8. PMID: 28499366; PMCID: PMC5429567.
701	31.	Aiad HA, Kandil MA, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA,
702		Aleskandarany MA. The prognostic and predictive significance of PARP-1 in locally advanced
703		breast cancer of Egyptian patients receiving neoadjuvant chemotherapy. Appl Immunohistochem
704		Mol Morphol. 2015 Sep;23(8):571-9. doi: 10.1097/PAI.00000000000124. PMID: 25611238.
705	32.	Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H, Moneer MM.
706		Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic
707		triple negative breast cancer. Clin Biochem. 2009 Sep;42(13-14):1420-6. doi:
708		10.1016/j.clinbiochem.2009.06.022. Epub 2009 Jul 2. PMID: 19576877.
709	33.	Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, Abodeef WT. Survival effects of
710		cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer. Indian J
711		Cancer. 2009 Jan-Mar;46(1):54-60. doi: 10.4103/0019-509x.48597. PMID: 19282568.

- 34. Slaoui M, Mouh FZ, Ghanname I, Razine R, El Mzibri M, Amrani M. Outcome of Breast Cancer
  in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and
  Treatment: A Comparative Study of 716 Cases in a Single Institution. PLoS One. 2016 Oct
  19;11(10):e0164841. doi: 10.1371/journal.pone.0164841. PMID: 27760178; PMCID:
  PMC5070817.
- 5. Ermiah E, Buhmeida A, Khaled BR, Abdalla F, Salem N, Pyrhönen S, Collan Y. Prognostic value of bcl-2 expression among women with breast cancer in Libya. Tumour Biol. 2013 Jun;34(3):1569-78. doi: 10.1007/s13277-013-0687-1. Epub 2013 Feb 16. PMID: 23417836.
- 36. Ngowa JDK, Kasia JM, Yomi J, Nana AN, Ngassam A, Domkam I, Sando Z, Ndom P. Breast
  Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaoundé General
  Hospital. Advances in Breast Cancer Research. 2015;4(2):44-52. doi: 10.4236/abcr.2015.42005.
- 37. Abdalla FB, Markus R, Buhmeida A, Boder J, Syrjänen K, Collan Y. Estrogen receptor,
  progesterone receptor, and nuclear size features in female breast cancer in Libya: correlation with
  clinical features and survival. Anticancer Res. 2012 Aug;32(8):3485-93. PMID: 22843935.
- 38. Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L, Kallel L, Gharbi O,
  Korbi S, Khaïri H, Kraïem C. Pronostic du cancer du sein chez les femmes tunisiennes: analyse
  d'une série hospitalière de 729 patientes [Breast cancer prognosis in Tunisian women: analysis of
  a hospital series of 729 patients]. Sante Publique. 2002 Sep;14(3):231-41. French. PMID:
  12564048.
- 39. Samaka RM, Younes SF. Androgen Receptor Expression in Breast Carcinoma of Egyptian
  Patients. J Clin Diagn Res. 2016 Nov;10(11):EC17-EC21. doi: 10.7860/JCDR/2016/23364.8919.
  Epub 2016 Nov 1. PMID: 28050375; PMCID: PMC5198328.
- 40. Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, et
  al. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.
  BMC Womens Health. 2016 Oct 22;16(1):68. doi: 10.1186/s12905-016-0346-y. PMID:
  27770782; PMCID: PMC5075166.
- 738 41. Traore B, Toure A, Sy T, Dieng MM, Conde M, Dem A, Keita N, Sylla BS. Five-year prognosis
  739 of breast cancer patients in Conakry Hospital University (West Africa). J Clin Oncol.
  740 2015;33(15\_Suppl):e12065. doi: 10.1200/jco.2015.33.15\_suppl.e12065.
- 42. Ayoade BA, Agboola AJ, Olatunji AA, Tade AO, Salami BA, Adekoya AO. Clinical characteristics and survival outcome of breast cancer in southwest Nigerian women. J Afr Cancer.
  2014;6:79–84. doi: 10.1007/s12558-014-0311-8.
- Zeeneldin AA, Ramadan M, Elmashad N, Fakhr I, Diaa A, Mosaad E. Breast cancer laterality
  among Egyptian patients and its association with treatments and survival. J Egypt Natl Canc Inst.
  2013 Dec;25(4):199-207. doi: 10.1016/j.jnci.2013.09.003. Epub 2013 Oct 25. PMID: 24207092.
- 44. Mohammad MA, Zeeneldin AA, Abd Elmageed ZY, Khalil EH, Mahdy SM, Sharada HM,
  Sharawy SK, Abdel-Wahab AH. Clinical relevance of cyclooxygenase-2 and matrix
  metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue. Mol Cell Biochem.
  2012 Jul;366(1-2):269-75. doi: 10.1007/s11010-012-1305-z. Epub 2012 Apr 18. PMID:
  22527932.
- 45. Kantelhardt EJ, Zerche P, Trocchi P, Mathios A, Reeler A, Tufa G, Yonas B, Stang A, et al. Breast cancer in Sub-Saharan Africa: 1,000 patients with primary breast cancer in Addis Ababa followed for up to 5 years. J Clin Oncol. 2012;30(15\_Suppl):580. doi: 10.1200/jco.2012.30.15\_suppl.580.
- 46. Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed with breast cancer in
  El-Minia Governorate, Egypt. Int J Prev Med. 2011 Jul;2(3):131-8. PMID: 21811654; PMCID:
  PMC3143525.

- 47. El Mongy M, El Hossieny H, Haggag F, Fathy R. Clinico-pathological study and treatment results
  of 1009 operable breast cancer cases: Experience of NCI Cairo University, Egypt. Chin. -Ger. J.
  Clin. Oncol. 2010; 9:409–415. doi: 10.1007/s10330-010-0614-5.
- 48. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO,
  et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet
  Oncol. 2010 Feb;11(2):165-73. doi: 10.1016/S1470-2045(09)70335-3. Epub 2009 Dec 10. PMID:
  20005175.
- 49. Kaabia O, Amine G, Nawel A, Feten H, Afraa B. Male Breast Cancer in Tunisia: Epidemiological and Clinical Features & Prognosis Factors. International Journal of Gynecological Cancer.
  2017;27(November Suppl 4):631 (ESGO7-1121). doi: 10.1097/01.IGC.0000527296.86225.87.
- 50. Alaoui Slimani K, Debbagh A, Sbitti Y, Errihani H, Ichou M. Cancer du sein chez l'homme au Maroc : épidémiologie et facteurs pronostiques. À propos de 140 cas [Male breast cancer in Morocco: Epidemiology and prognostic factors. A report of 140 cases]. Gynecol Obstet Fertil. 2016 Nov;44(11):636-640. French. doi: 10.1016/j.gyobfe.2016.08.009. Epub 2016 Sep 23. PMID: 27671207.
- 51. El-Beshbeshi W, Abo-Elnaga EM. Male breast cancer: 10-year experience at mansoura university
  hospital in egypt. Cancer Biol Med. 2012 Mar;9(1):23-8. doi: 10.3969/j.issn.20953941.2012.01.004. PMID: 23691450; PMCID: PMC3643641.
- 52. El-Baradie M, Salama A, Khorshid O, Ismail H, Attia G, Abeer A. Egyptian male breast carcinoma: patients' hormonal profile, management and outcome. Chin.-Ger. J. Clin. Oncol. 2012; 11:89–98. doi: 10.1007/s10330-011-0918-0.

779 780

- 53. Bourhafour M, Belbaraka R, Souadka A, M'rabti H, Tijami F, Errihani H. Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res Notes. 2011 Jun 29;4:219. doi: 10.1186/1756-0500-4-219. PMID: 21714875; PMCID: PMC3143075.
- 54. Ihekwaba FN. The management of male breast cancer in Nigerians. Postgrad Med J. 1993
  Jul;69(813):562-5. doi: 10.1136/pgmj.69.813.562. PMID: 8415345; PMCID: PMC2399872.
- 55. Bouzid N, Lahmar R, Tebra S, Bouaouina N. Cancer du sein chez la femme jeune de moins de 35
  ans en Tunisie: étude rétrospective à propos de 124 cas [Breast cancer in woman younger than 35
  years in Tunisia: retrospective study about 124 cases]. Gynecol Obstet Fertil. 2013 Jun;41(6):35660. French. doi: 10.1016/j.gyobfe.2013.05.002. Epub 2013 Jun 7. PMID: 23747138.
- 56. Khanfir A, Frikha M, Kallel F, Meziou M, Trabelsi K, Boudawara T, Mnif J, Daoud J. Le cancer du sein de la femme jeune dans le sud tunisien [Breast cancer in young women in the south of Tunisia]. Cancer Radiother. 2006 Dec;10(8):565-71. French. doi: 10.1016/j.canrad.2006.09.115.
  Epub 2006 Nov 30. PMID: 17140835.
- 57. Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, Barakat A, Ghailani
  Nourouti N, et al. Clinicopathologic and prognostic features of breast cancer in young women: a
  series from North of Morocco. BMC Womens Health. 2017 Nov 9;17(1):106. doi:
  10.1186/s12905-017-0456-1. PMID: 29121898; PMCID: PMC5680801.
- 58. Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
  Pathol Oncol Res. 2015 Jul;21(3):553-61. doi: 10.1007/s12253-015-9944-5. Epub 2015 May 12.
  PMID: 25962349.
- 59. Kallel M, Elloumi F, Khabir A, Ghorbal L, Chaabouni S, Amouri H, Frikha M, Daoud J. Breast cancer in young women in southern Tunisia: Anatomical study and clinical prognostic factors:
  About a series of 83 patients. Rep Pract Oncol Radiother. 2015 May-Jun;20(3):155-60. doi: 10.1016/j.rpor.2015.01.007. Epub 2015 Mar 6. PMID: 25949218; PMCID: PMC4418592.

- Khelifi O, Zeghal D, Jeridi S, Ben Hmid R, Zouari F, Mahjoub S. Young women's breast cancer.
  International Journal of Gynecology and Obstetrics. 2012;119(Suppl\_3):S630 (M307). doi: 10.1016/S0020-7292(12)61498-2.
- 807 61. Basro S, Apffelstaedt JP. Breast cancer in young women in a limited-resource environment. World
  808 J Surg. 2010 Jul;34(7):1427-33. doi: 10.1007/s00268-009-0299-5. PMID: 19997919.
- 809 62. Parag Y, Buccimazza I. How long are elderly patients followed up with mammography after the diagnosis of breast cancer? A single-centre experience in a developing country. S Afr Med J. 2016
  811 Jun 17;106(7):721-3. doi: 10.7196/SAMJ.2016.v106i7.10405. PMID: 27384369.
- 812 63. Zongo N, Ouédraogo S, Korsaga-Somé N, Somé OR, Go N, Ouangré E, Zida M, Bonkoungou G,
  813 et al. Male breast cancer: diagnosis stages, treatment and survival in a country with limited
  814 resources (Burkina Faso). World J Surg Oncol. 2018 Jan 11;16(1):4. doi: 10.1186/s12957-017815 1297-y. PMID: 29325566; PMCID: PMC5765600.
- 64. Ahmed A, Ukwenya Y, Abdullahi A, Muhammad I. Management and outcomes of male breast cancer in zaria, Nigeria. Int J Breast Cancer. 2012;2012:845143. doi: 10.1155/2012/845143. Epub
  2012 Sep 6. PMID: 22991670; PMCID: PMC3443591.
- 65. Elshafiey MM, Zeeneldin AA, Elsebai HI, Moneer M, Mohamed DB, Gouda I, Attia AA.
  Epidemiology and management of breast carcinoma in Egyptian males: experience of a single
  Cancer Institute. J Egypt Natl Canc Inst. 2011 Sep;23(3):115-22. doi: 10.1016/j.jnci.2011.10.001.
  Epub 2011 Nov 18. PMID: 22776816.

- 66. El-Habbash MM, Alwindi AA. Male breast cancer in Tripoli, Libya. Saudi Med J. 2009 Aug;30(8):1060-2. PMID: 19668888.
- 825 67. Ben Dhiab T, Bouzid T, Gamoudi A, Ben Hassouna J, Khomsi F, Boussen H, Benna F, El May A,
  826 et al. Le cancer du sein chez l'homme: à propos de 123 cas colligés à l'institut Salah-Azaïz de
  827 Tunis de 1979 à 1999 [Male breast cancer: about 123 cases collected at the Institute Salah-Azaïz
  828 of Tunis from 1979 to 1999]. Bull Cancer. 2005 Mar;92(3):281-5. French. PMID: 15820923.
- 68. Tabbane F, Muenz L, Jaziri M, Cammoun M, Belhassen S, Mourali N. Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia. Cancer. 1977 Jul;40(1):376-82. doi: 10.1002/1097-0142(197707)40:1<376::aid-cncr2820400153>3.0.co;2-y. PMID: 880564.
- 69. Mabula JB, Mchembe MD, Chalya PL, Giiti G, Chandika AB, Rambau P, Masalu N, Gilyomai
  JM. Stage at diagnosis, clinicopathological and treatment patterns of breast cancer at Bugando
  Medical Centre in north-western Tanzania. Tanzan J Health Res. 2012 Oct;14(4):269-79. PMID:
  26591725.
- 836 70. Ben Gobrane H, Fakhfakh R, Rahal K, Ben Ayed F, Mâalej M, Ben Abdallah M, Achour N, Hsairi
  837 M. Pronostic du cancer du sein à l'Institut de Carcinologie Salah Azaïez de Tunis [Breast cancer
  838 prognosis in Salah Azaïez Institute of Cancer, Tunis]. East Mediterr Health J. 2007 Mar839 Apr;13(2):309-18. French. PMID: 17684853.
- 840 71. Weiner CM, Mathewos A, Addissie A, Ayele W, Aynalem A, Wondemagegnehu T, Wienke A,
  841 Jemal A, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort
  842 study of 573 women. Breast. 2018 Dec;42:23-30. doi: 10.1016/j.breast.2018.08.095. Epub 2018
  843 Aug 7. PMID: 30149234.
- 844 72. Ersumo T, Tamrat G, Solomon B, Gero T. Breast cancer in a private medical services center: a 10845 year experience. Ethiopian Medical Journal. 2018;56(3):211-218. Available from
  846 <u>https://emjema.org/index.php/EMJ/article/view/857</u> (accessed 29th November 2024).
- 847 73. Shiferaw WS, Aynalem YA, Akalu TY, Demelew TM. Incidence and Predictors of Recurrence
  848 among Breast Cancer Patients in Black Lion Specialized Hospital Adult Oncology Unit, Addis
  849 Ababa, Ethiopia: Retrospective Follow-up Study with Survival Analysis. J Cancer Prev. 2020 Jun
  850 30;25(2):111-118. doi: 10.15430/JCP.2020.25.2.111. PMID: 32647652; PMCID: PMC7337003.

- 74. Fouhi ME, Mesfioui A, Benider A. Male breast cancer: a report of 25 cases. Pan Afr Med J. 2020
  Dec 15;37:343. doi: 10.11604/pamj.2020.37.343.23004. PMID: 33738031; PMCID: PMC7934185.
- 75. Abdalla Elhassan SI. The five-year survival rate of breast cancer at Radiation and Isotopes Centre
  Khartoum, Sudan. Heliyon. 2020 Aug 20;6(8):e04615. doi: 10.1016/j.heliyon.2020.e04615.
  PMID: 32904288; PMCID: PMC7452576.
- 76. Zingue S, Atenguena EO, Zingue LL, Tueche AB, Njamen D, Nkoum AB, Ndom P.
  Epidemiological and clinical profile, and survival of patients followed for breast cancer between
  2010 and 2015 at the Yaounde General Hospital, Cameroon. Pan Afr Med J. 2021 Jul 7;39:182.
  doi: 10.11604/pamj.2021.39.182.26866. PMID: 34466203; PMCID: PMC8378266.
- 77. Ali-Gombe M, Mustapha MI, Folasire A, Ntekim A, Campbell OB. Pattern of survival of breast cancer patients in a tertiary hospital in South West Nigeria. Ecancermedicalscience. 2021 Feb 25;15:1192. doi: 10.3332/ecancer.2021.1192. PMID: 33889201; PMCID: PMC8043689.
- 78. Tiruneh M, Tesfaw A, Tesfa D. Survival and Predictors of Mortality among Breast Cancer
  Patients in Northwest Ethiopia: A Retrospective Cohort Study. Cancer Manag Res. 2021 Dec
  16;13:9225-9234. doi: 10.2147/CMAR.S339988. PMID: 34938122; PMCID: PMC8687444.
- 79. Muddather HF, Elhassan MMA, Faggad A. Survival Outcomes of Breast Cancer in Sudanese
  Women: A Hospital-Based Study. JCO Glob Oncol. 2021 Feb;7:324-332. doi: 10.1200/GO.20.00538. PMID: 33617296; PMCID: PMC8081542.
- 870 80. Wambua MD, Degu A, Tegegne GT. Treatment outcomes and its associated factors among breast cancer patients at Kitui Referral Hospital. SAGE Open Med. 2022 Jan 8;10:20503121211067857.
  872 doi: 10.1177/20503121211067857. PMID: 35024144; PMCID: PMC8744162.
- 873 81. Wuraola FO, Olasehinde O, Di Bernardo M, Akinkuolie AA, Adisa AO, Aderounmu AA,
  874 Mohammed TO, Omoyiola OZ, et al. Breast cancer in elderly patients: a clinicopathological
  875 review of a Nigerian database. Ecancermedicalscience. 2022 Dec 8;16:1484. doi:
  876 10.3332/ecancer.2022.1484. PMID: 36819793; PMCID: PMC9934965.
- 877 82. Matheka M, Mutebi M, Sayed S, Shah J, Shaikh AJ. Metastatic breast cancer in Kenya: survival,
  878 prognosis and management at a tertiary referral centre. Ecancermedicalscience. 2023 Jun
  879 27;17:1566. doi: 10.3332/ecancer.2023.1566. PMID: 37396100; PMCID: PMC10310329.
- 83. Gnangnon FHR, Parenté A, Aboubakar M, Kiki-Migan Y, Totah T, Gbessi DG, Tonato-Bagnan JA, Laleye A, et al. Prognostic factors and overall survival of breast cancer in Benin: a hospital-based study. BMC Womens Health. 2024 May 18;24(1):295. doi: 10.1186/s12905-024-03114-y.
  883 PMID: 38762733; PMCID: PMC11102149.

884

- 84. Soliman M. Squamous cell carcinoma of the breast: A retrospective study. J Cancer Res Ther. 2019 Jul-Sep;15(5):1057-1061. doi: 10.4103/jcrt.JCRT\_303\_17. PMID: 31603110.
- 886 85. Olasehinde O, Alatise O, Omisore A, Wuraola F, Odujoko O, Romanoff A, Akinkuolie A,
  887 Arowolo O, et al. Contemporary management of breast cancer in Nigeria: Insights from an
  888 institutional database. Int J Cancer. 2021 Jun 15;148(12):2906-2914. doi: 10.1002/ijc.33484.
  889 Epub 2021 Feb 9. PMID: 33506499; PMCID: PMC8394611.
- 86. Chokunonga E, Borok MZ, Chirenje ZM, Nyabakau AM, Parkin DM. Cancer survival in Harare,
  Zimbabwe, 1993-1997. IARC Sci Publ. 2011;(162):249-55. PMID: 21675430.
- 87. Bah E, Sam O, Whittle H, Ramanakumar A, Sankaranarayanan R. Cancer survival in the Gambia,
  1993-1997. IARC Sci Publ. 2011;(162):97-100. PMID: 21675410.
- 88. Wabinga H, Parkin DM, Nambooze S, Amero J. Cancer survival in Kampala, Uganda, 19931997. IARC Sci Publ. 2011;(162):243-7. PMID: 21675429.

- 896 89. Otu AA, Ekanem IO, Khalil MI, Ekpo MD, Attah EB. Characterization of breast cancer
  897 subgroups in an African population. Br J Surg. 1989 Feb;76(2):182-4. doi:
  898 10.1002/bjs.1800760225. PMID: 2702455.
- 899 90. Okobia MN, Osime U. Clinicopathological study of carcinoma of the breast in Benin City. Afr J
  900 Reprod Health. 2001 Aug;5(2):56-62. PMID: 12471913.
- 901 91. Elhaj AM, Abdalsalam AI, Abuidris AO, Eltayeb AA. Overall survival of females with breast cancer in the National Cancer Institute, University of Gezira, Sudan. Sudan Medical Monitor.
  903 2015;10(1):1-6. doi: 10.4103/1858-5000.157499.
- 904 92. Mensah AC, Yarney J, Nokoe SK, Opoku S, Clegg-Lamptey JN. Survival outcomes of breast cancer in Ghana: an analysis of clinicopathological features. Open Access Library Journal. 2016;3(1):e2145. doi: 10.4236/oalib.1102145.
- 907 93. Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N'da G, Assefa M,
  908 Buziba N, Korir A, et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis
  909 and human development index: A population-based registry study. Int J Cancer. 2020 Mar
  910 1;146(5):1208-1218. doi: 10.1002/ijc.32406. Epub 2019 Jun 14. PMID: 31087650; PMCID:
  911 PMC7079125.
- 912 94. Some OR, Bague AH, Konkobo D, Hien D, Dembele A, Hermann Belemlilga GL, Konsegre V,
  913 Zongo N. Le Cancer du Sein à Bobo-Dioulasso, Burkina Faso: Résultats de la Prise en Charge.
  914 Oncologie. 2022;24(2):173-184. doi: 10.32604/oncologie.2022.021250.
- 915 95. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br J
   916 Cancer. 2005 May 9;92(9):1808-12. doi: 10.1038/sj.bjc.6602540. PMID: 15827554; PMCID:
   917 PMC2362045.
- 918 96. Traore B, Keita M, Toure A, Camara I, Barry A, Koulibaly M. Impact of surgery associated with
  919 radiotherapy on the prognosis of breast cancer Guinea Breast Cancer Cohort Study. Cancer Rep
  920 (Hoboken). 2022 Sep;5(9):e1554. doi: 10.1002/cnr2.1554. Epub 2021 Sep 22. PMID: 34549551;
  921 PMCID: PMC9458488.
- 922 97. Maajani K, Jalali A, Alipour S, Khodadost M, Tohidinik HR, Yazdani K. The Global and
  923 Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis.
  924 Clin Breast Cancer. 2019 Jun;19(3):165-177. doi: 10.1016/j.clbc.2019.01.006. Epub 2019 Jan 29.
  925 PMID: 30952546.
- 926 98. Quang DT, Luong Thi T, Nguyen Di K, Vu Thi Quynh C, Nguyen Thi Hoa H, Phan Ngoc Q.
  927 Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review
  928 and meta-analysis spanning four decades. Curr Probl Cancer. 2024 Feb;48:101062. doi:
  929 10.1016/j.currproblcancer.2024.101062. Epub 2024 Feb 2. PMID: 38309146.
- 930 99. Maajani K, Khodadost M, Fattahi A, Pirouzi A. Survival rates of patients with breast cancer in countries in the Eastern Mediterranean Region: a systematic review and meta-analysis. East Mediterr Health J. 2020 Feb 24;26(2):219-232. doi: 10.26719/2020.26.2.219. PMID: 32141601.
- 933 100. Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E.
  934 Male breast cancer. Cancer Treat Rev. 2010 Oct;36(6):451-7. doi: 10.1016/j.ctrv.2010.02.002.
  935 Epub 2010 Mar 2. PMID: 20193984.
- 101. Scomersi S, Giudici F, Cacciatore G, Losurdo P, Fracon S, Cortinovis S, Ceccherini R, Zanconati F, Tonutti M, Bortul M. Comparison between male and female breast cancer survival using propensity score matching analysis. Sci Rep. 2021 Jun 2;11(1):11639. doi: 10.1038/s41598-021-939
  91131-4. PMID: 34079019; PMCID: PMC8172634.
- 940 102. Gwark S, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Lee SB. Survival pattern
  941 in male breast cancer: distinct from female breast cancer. Front Oncol. 2024 Jun 28;14:1392592.
  942 doi: 10.3389/fonc.2024.1392592. PMID: 39007102; PMCID: PMC11239393.

- 943 103. Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, Mellemkjær L,
  944 Czene K, Hartman M. Incidence and outcome of male breast cancer: an international population945 based study. J Clin Oncol. 2011 Nov 20;29(33):4381-6. doi: 10.1200/JCO.2011.36.8902. Epub
  946 2011 Oct 3. PMID: 21969512.
- 947 104. Varzaru VB, Anastasiu-Popov DM, Eftenoiu AE, Popescu R, Vlad DC, Vlad CS, Moatar AE,
  948 Puscasiu D, Cobec IM. Observational Study of Men and Women with Breast Cancer in Terms of
  949 Overall Survival. Cancers (Basel). 2024 Sep 1;16(17):3049. doi: 10.3390/cancers16173049.
  950 PMID: 39272907; PMCID: PMC11394319.
- 951 105. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, et
  952 al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006
  953 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492. PMID: 16757721.
- 954 106. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, et al.
  955 NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021
  956 May 1;19(5):484-493. doi: 10.6004/jnccn.2021.0023. PMID: 34794122.
- 957 107. Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American
  958 women: a review. J Natl Med Assoc. 2008 Jun;100(6):698-702. doi: 10.1016/s0027959 9684(15)31344-4. PMID: 18595572.
- 960 108. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507. doi: 10.1007/s13346-018-0551-3. PMID: 29978332; PMCID: PMC6133085.
- 963 109. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. PMID: 20537966; PMCID: PMC5527939.
- 967 110. Martini R, Chen Y, Jenkins BD, Elhussin IA, Cheng E, Hoda SA, Ginter PS, Hanover J, et al.
  968 Investigation of triple-negative breast cancer risk alleles in an International African-enriched
  969 cohort. Sci Rep. 2021 Apr 29;11(1):9247. doi: 10.1038/s41598-021-88613-w. PMID: 33927264;
  970 PMCID: PMC8085076.
- 111. Koon Sun Pat M, Manraj M, Manraj S. Breast cancer survival analysis in the Republic of Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study. Int J Cancer. 2025 Jan 15;156(2):331-338. doi: 10.1002/ijc.35172. Epub 2024 Sep 7. PMID: 39243396.
- 975 112. Sanyang O, Lopez-Verdugo F, Mali M, Moustafa M, Nellermoe J, Sorensen J, Bittaye M, Njie R,
  976 et al. Geospatial analysis and impact of targeted development of breast cancer care in The
  977 Gambia: a cross-sectional study. BMC Health Serv Res. 2021 Sep 9;21(1):943. doi:
  978 10.1186/s12913-021-06963-7. PMID: 34503503; PMCID: PMC8428029.
- 979 113. World Health Organization. Atlas of African Health Statistics 2022: Health situation analysis of
   980 the WHO African Region Country profiles. Brazzaville: WHO Regional Office for Africa.
   981 2022 [online]. Available from <u>https://www.afro.who.int/publications/atlas-african-health-</u>
   982 statistics-2022-health-situation-analysis-who-african-region-0 (accessed 30th November 2024).
- 114. Lombe DC, Mwamba M, Msadabwe S, Bond V, Simwinga M, Ssemata AS, Muhumuza R, Seeley
  J, Mwaka AD, et al. Delays in seeking, reaching and access to quality cancer care in sub-Saharan
  Africa: a systematic review. BMJ Open. 2023 Apr 13;13(4):e067715. doi: 10.1136/bmjopen2022-067715. PMID: 37055211; PMCID: PMC10106057.
- 987 115. Round JI. Globalization, Growth, Inequality and Poverty in Africa: A Macroeconomic
   988 Perspective. Research Paper 2007/055 Helsinki: UNU-WIDER. 2007 [online]. Available from

989	https://www.wider.unu.edu/publication/globalization-growth-inequality-and-poverty-africa
990	(accessed 30th November 2024).
991	116. Ichoku HE, Mooney G, Ataguba JE. Africanizing the social determinants of health: embedded
992	structural inequalities and current health outcomes in sub-Saharan Africa. Int J Health Serv.
993	2013;43(4):745-59. doi: 10.2190/HS.43.4.i. PMID: 24397237.
994	117. James PB, Asiimwe JB, Wardle J, Mwaka AD, Kasilo OMJ. African culture, traditional medicine,
995	and cancer care. Lancet Oncol. 2022 Jun;23(6):705-706. doi: 10.1016/S1470-2045(22)00157-7.
996	Epub 2022 May 9. PMID: 35550271.
997	118. Tetteh DA, Faulkner SL. Sociocultural factors and breast cancer in sub-Saharan Africa:
998	implications for diagnosis and management. Womens Health (Lond). 2016 Jan;12(1):147-56. doi:
999	10.2217/whe.15.76. Epub 2016 Jan 12. PMID: 26757491; PMCID: PMC5779571.
1000	119. Mansour R, Abdel-Razeq H, Al-Hussaini M, Shamieh O, Al-Ibraheem A, Al-Omari A, Mansour
1001	AH. Systemic Barriers to Optimal Cancer Care in Resource-Limited Countries: Jordanian

- AH. Systemic Barriers to Optimal Cancer Care in Resource-Limited Countries: Jordanian
  Healthcare as an Example. Cancers (Basel). 2024 Mar 11;16(6):1117. doi:
  1003 10.3390/cancers16061117. PMID: 38539452; PMCID: PMC10968872.
- 1004 120. Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2016
  1006 Dec;4(12):e923-e935. doi: 10.1016/S2214-109X(16)30259-5. PMID: 27855871; PMCID: PMC5708541.